CSIMarket
 


Innoviva Inc   (INVA)
Other Ticker:  
 

Innoviva Inc 's Long Term Debt to Equity

INVA's quarterly Long Term Debt to Equity and Long Term Debt, Equity growth


Despite a net increase in long-term borrowings by 0.23%, Innoviva Inc managed to enhance Long Term Debt to Equity in the third quarter 2023 to 0.71, falling below the company's typical Long Term Debt to Equity.

Within Major Pharmaceutical Preparations industry in the third quarter 2023, 18 other companies have achieved lower Long Term Debt to Equity than Innoviva Inc in the III Quarter 2023. While Long Term Debt to Equity total ranking has improved so far in the third quarter 2023 to 657, from total ranking in the first quarter 2023 at 1777 .

Explain Long Term Debt to Equity Ratio?
How much Long Term Debt INVA´s has?
What is the structure of INVA´s Equity?


INVA Long Term Debt to Equity (Sep 30 2023)
III. Quarter
(Mar 31 2023)
I. Quarter
(Dec 31 2022)
IV. Quarter
(Sep 30 2022)
III. Quarter
(Jun 30 2022)
II. Quarter
Y / Y Equity Change 10.97 % 1.68 % 7.58 % 30.41 % 43.61 %
Y / Y Long Term Debt Change 0.57 % 0.44 % 12.55 % 13.1 % 13.64 %
Long Term Debt to Equity MRQ 0.71 0.79 0.79 0.69 0.78
INVA's Total Ranking # 657 # 1777 # 1089 # 1633 #
Seq. Equity Change 11.75 % -0.76 % -11.78 % 13.42 % 2.4 %
Seq. Long Term Debt Change 0.23 % 0.12 % 0.11 % 0.11 % 0.1 %



Long Term Debt to Equity third quarter 2023 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 19
Healthcare Sector # 56
Overall Market # 657


Long Term Debt to Equity Statistics
High Average Low
28.14 2.17 0.56
(Mar 31 2012)   (Mar 31 2021)




Financial Statements
Innoviva Inc 's Equity $ 627 Millions Visit INVA's Balance sheet
Innoviva Inc 's Long Term Debt $ 446 Millions Visit INVA's Balance sheet
Source of INVA's Sales Visit INVA's Sales by Geography


Cumulative Innoviva Inc 's Long Term Debt to Equity

INVA's Long Term Debt to Equity for the trailling 12 Months

INVA Long Term Debt to Equity

(Sep 30 2023)
III. Quarter
(Mar 31 2023)
I. Quarter
(Dec 31 2022)
IV. Quarter
(Sep 30 2022)
III. Quarter
(Jun 30 2022)
II. Quarter
Y / Y Equity TTM Growth 10.97 % 1.68 % 7.58 % 30.41 % 43.61 %
Y / Y Long Term Debt TTM Growth 0.57 % 0.44 % 12.55 % 13.1 % 13.64 %
Long Term Debt to Equity TTM 0.74 0.76 0.76 0.75 0.78
Total Ranking TTM # 235 # 120 # 123 # 78 #
Seq. Equity TTM Growth 11.75 % -0.76 % -11.78 % 13.42 % 2.4 %
Seq. Long Term Debt TTM Growth 0.23 % 0.12 % 0.11 % 0.11 % 0.1 %


On the trailing twelve months basis Despite of the net new long-term borrowings of 0.23% during the twelve months period ending in III Quarter 2023 Innoviva Inc has managed to decrease Long Term Debt to Equity in the III Quarter 2023 to 0.74, below Innoviva Inc 's average Long Term Debt to Equity.
Long Term Debt to Equity is the average cumulative value over the last four quarters.

Among companies in the Major Pharmaceutical Preparations industry 35, during the past 12 months, other companies have achieved lower Long Term Debt to Equity than Innoviva Inc . While Long Term Debt to Equity total ranking has deteriorated during the twelve months ending in the III Quarter 2023, compared to the prior period, from 120 to 235.

Explain Long Term Debt to Equity Ratio?
How much Long Term Debt INVA´s has?
What is the structure of INVA´s Equity?

TTM Long Term Debt to Equity Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 36
Healthcare Sector # 71
Within the Market # 235


trailing twelve months Long Term Debt to Equity Statistics
High Average Low
17.15 1.92 0.66
(Mar 31 2019)   (Mar 31 2021)




Companies with similar Long Term Debt to Equity in the quarter ending Sep 30 2023, within Major Pharmaceutical Preparations Industry Long Term Debt to EquitySep 30 2023 MRQ Long Term DebtSep 30 2023 MRQ Equity
Ionis Pharmaceuticals Inc  1.78 $ 561.609  Millions$ 315.460  Millions
Milestone Pharmaceuticals inc   1.72 $ 48.915  Millions$ 28.504  Millions
Phibro Animal Health Corporation  1.68 $ 458.717  Millions$ 273.069  Millions
Sarepta Therapeutics Inc   1.62 $ 1,236.755  Millions$ 764.357  Millions
Eli Lilly And Company  1.59 $ 17,923.600  Millions$ 11,307.400  Millions
Jazz Pharmaceuticals Plc  1.46 $ 5,110.757  Millions$ 3,489.373  Millions
Travere Therapeutics Inc   1.35 $ 376.833  Millions$ 279.766  Millions
Alimera Sciences Inc   1.31 $ 64.222  Millions$ 48.840  Millions
Zoetis Inc   1.29 $ 6,552.000  Millions$ 5,074.000  Millions
Cerevel Therapeutics Holdings Inc   1.23 $ 336.933  Millions$ 272.962  Millions
Blueprint Medicines Corporation  1.20 $ 243.294  Millions$ 202.611  Millions
G1 Therapeutics Inc   1.19 $ 51.246  Millions$ 43.022  Millions
Marinus Pharmaceuticals Inc   1.19 $ 64.783  Millions$ 54.537  Millions
Mirum Pharmaceuticals Inc   1.14 $ 306.022  Millions$ 269.081  Millions
Catalent Inc   1.13 $ 4,322.000  Millions$ 3,841.000  Millions
Bristol myers Squibb Company  1.11 $ 32,137.000  Millions$ 29,062.000  Millions
Syros Pharmaceuticals Inc   1.09 $ 39.406  Millions$ 36.302  Millions
Amphastar Pharmaceuticals Inc   1.07 $ 638.206  Millions$ 595.140  Millions
Petros Pharmaceuticals inc   1.05 $ 7.249  Millions$ 6.933  Millions
Verrica Pharmaceuticals Inc   1.00 $ 42.401  Millions$ 42.303  Millions
Eterna Therapeutics Inc   0.97 $ 3.452  Millions$ 3.562  Millions
Elanco Animal Health Inc  0.96 $ 5,870.000  Millions$ 6,134.000  Millions
Pds Biotechnology Corp  0.96 $ 23.413  Millions$ 24.484  Millions
Perrigo Company Plc  0.85 $ 4,048.500  Millions$ 4,738.100  Millions
Merck and Co Inc   0.82 $ 33,972.000  Millions$ 41,300.000  Millions
Prestige Consumer Healthcare Inc   0.82 $ 1,262.972  Millions$ 1,535.959  Millions
Viatris Inc   0.82 $ 17,076.900  Millions$ 20,865.600  Millions
Rani Therapeutics Holdings Inc   0.81 $ 28.101  Millions$ 34.819  Millions
Scpharmaceuticals Inc   0.78 $ 38.262  Millions$ 49.146  Millions
Avid Bioservices Inc   0.77 $ 141.154  Millions$ 183.675  Millions

Date modified: 2023-11-02T13:11:55+00:00



Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com